CME vs. Morningstar: Which Financial Stock Is a Better Buy in 2026?

The article favors CME Group over Morningstar, citing CME’s 2025 revenue of $6.5 billion, net margin of about 62%, and debt-to-equity ratio of approximately 0.12x; third-quarter 2026 average daily volume reached a record 29.4 million contracts, up 16% year over year. Morningstar’s revenue grew 9.6% to $663.2 million in Q2 2026, but its debt-to-equity ratio had risen to about 1.7x by June 30 after the $363 million CRSP acquisition and share repurchases, while PitchBook licensed user counts were relatively flat. Morningstar trades at lower forward P/E and price-to-sales multiples, but the author views its leverage as a risk and CME’s premium valuation as vulnerable if trading volumes slow.

Analysis

The key distinction is earnings durability, not simply CME’s margin versus Morningstar’s lower multiple. CME’s record activity is a cyclical tailwind that can reverse as volatility and hedging demand normalize; a premium valuation leaves less room for that mean reversion. The Oct. 21 report is the near-term test: watch transaction-fee growth and volume mix, not headline contract counts alone. A 12% fee-customer concentration and a major market outage are asymmetric risks because exchange liquidity and confidence can be disrupted quickly, although an outage could temporarily redirect flow to ICE or CBOE without necessarily changing long-run market share.

Morningstar’s discount may understate execution risk: higher leverage after CRSP and buybacks makes integration, refinancing costs, and cash conversion more consequential. Conversely, a strong operating-income trend and CRSP cross-selling could make the valuation gap look excessive if acquired data renewals and margins hold. AI scraping is a longer-horizon threat, but enterprise workflow integration and licensed data rights may blunt low-cost substitutes. CME’s planned Treasury clearing is a possible multi-year growth option, not yet a proven earnings catalyst; regulatory approval and adoption determine value. The contrarian risk to favoring CME is that exceptional trading activity is already reflected in its premium, while Morningstar’s lower valuation could rerate on continued operating leverage. No basis here to quantify either company’s intrinsic value.

Key Decisions for Investors

• Prefer CME over MORN on a relative basis, but avoid chasing into the Oct. 21 earnings event. Consider a small, risk-defined long CME / short MORN pair only if CME’s fee growth remains firm and MORN’s leverage or PitchBook trends disappoint; size for the possibility that volatility normalizes and MORN’s operating leverage persists.
• For CME, verify Q3 transaction-fee growth, volume mix, and commentary on customer concentration. Reassess the long thesis if fees weaken despite elevated volume, guidance implies sustained deceleration, or operational resilience concerns recur.
• For MORN, treat the lower multiple as a watchlist opportunity rather than an automatic buy. The Oct. 28 report should clarify PitchBook user and revenue momentum, CRSP integration/cross-sell, cash generation, and debt trajectory; improving these metrics would challenge the relative short thesis.
• Track SEC approval and participant adoption ahead of CME’s planned Treasury-clearing launch. Until there is evidence of volumes and economics, assign limited value to the initiative; delays or weak adoption would remove a potential medium-term catalyst.